RVL Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RVLP) $0.0037 0.00 (0.00%) (As of 11/27/2023 ET) Add Compare Share Share Today's Range$0.0027▼$0.004450-Day Range$0.00▼$0.1952-Week Range$0.03▼$1.91Volume2.77 million shsAverage VolumeN/AMarket Capitalization$406,646.50P/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media RVL Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside68,393.2% Upside$2.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$348,059 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.46) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 stars 3.5 Analyst's Opinion Consensus RatingRVL Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, RVL Pharmaceuticals has a forecasted upside of 68,393.2% from its current price of $0.00.Amount of Analyst CoverageRVL Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for RVLP. Previous Next 0.0 Dividend Strength Dividend YieldRVL Pharmaceuticals does not currently pay a dividend.Dividend GrowthRVL Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVLP. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for RVLP on MarketBeat in the last 30 days. This is a decrease of -98% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added RVL Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RVL Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $348,059.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of RVL Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 24.20% of the stock of RVL Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for RVL Pharmaceuticals are expected to grow in the coming year, from ($0.46) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RVL Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RVL Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRVL Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RVL Pharmaceuticals Stock (NASDAQ:RVLP)RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.Read More RVLP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVLP Stock News HeadlinesOctober 13, 2023 | marketwatch.comRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For BankruptcyOctober 12, 2023 | benzinga.comSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for BankruptcyNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 12, 2023 | markets.businessinsider.comRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be CancelledOctober 12, 2023 | finance.yahoo.comRVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 6, 2023 | investorplace.comWhy Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?August 23, 2023 | finance.yahoo.comUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 21, 2023 | markets.businessinsider.comRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. WainwrightAugust 16, 2023 | benzinga.comCrude Oil Falls Sharply; RVL Pharmaceuticals Shares PlummetAugust 16, 2023 | msn.comRVLP: Second Quarter ResultsAugust 16, 2023 | marketwatch.comRVL Pharmaceuticals Shares Hit New Lows After Stock Sale >RVLPAugust 16, 2023 | msn.comRVL Pharmaceuticals shares fall after pricing $5M stock offeringAugust 16, 2023 | finance.yahoo.comDowngrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near TermAugust 16, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesAugust 15, 2023 | finance.yahoo.comQ2 2023 RVL Pharmaceuticals PLC Earnings CallAugust 14, 2023 | msn.comRVLP: Revenue Dip Prompts Spending ReversalAugust 14, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business ReviewJuly 20, 2023 | finance.yahoo.comInsiders Re-Evaluate Their US$1.6m Stock Purchase As RVL Pharmaceuticals Falls To US$43mJuly 5, 2023 | msn.comRVL Pharma (NASDAQ:RVLP) Rises on Mulling A Strategic TransactionJuly 5, 2023 | benzinga.comRVL Pharmaceuticals shares are trading higher after the company said it has been considering certain strategic alternatives.June 15, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General MeetingJune 2, 2023 | finance.yahoo.comShareholders in RVL Pharmaceuticals (NASDAQ:RVLP) are in the red if they invested three years agoMay 13, 2023 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their RVL Pharmaceuticals plc (NASDAQ:RVLP) OutlookMay 12, 2023 | finance.yahoo.comRVLP: First Quarter ResultsMay 12, 2023 | msn.comRVL Pharmaceuticals: Q1 Earnings InsightsSee More Headlines Receive RVLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2023Today11/28/2023Next Earnings (Estimated)11/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVLP CUSIPN/A CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$3.00 Low Stock Price Target$2.00 Potential Upside/Downside+68,393.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,690,000.00 Net Margins-184.91% Pretax Margin-185.66% Return on Equity-130.22% Return on Assets-47.70% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.36 Sales & Book Value Annual Sales$49.72 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book0.01Miscellaneous Outstanding Shares111,410,000Free Float106,504,000Market Cap$406,646.50 OptionableOptionable Beta1.32 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 64)Chairman, President, CEO & Principal Financial Officer Comp: $525kMr. James D. Schaub (Age 41)Executive VP & COO Comp: $367.2kMr. Christopher A. Klein (Age 58)General Counsel & Secretary Comp: $367.2kMr. Michael J. DePetris (Age 46)Principal Accounting Officer Mr. Jarret MillerExecutive Vice President of Human ResourcesKey CompetitorsBellerophon TherapeuticsNASDAQ:BLPHBaudax BioNASDAQ:BXRXOncorusNASDAQ:ONCRGalmed PharmaceuticalsNASDAQ:GLMDContraFectNASDAQ:CFRXView All CompetitorsInsidersLtd AltchemSold 4,758,899 sharesTotal: $142,766.97 ($0.03/share)Foundation HarsaulSold 3,421,537 sharesTotal: $205,292.22 ($0.06/share)View All Insider Transactions RVLP Stock Analysis - Frequently Asked Questions Should I buy or sell RVL Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVLP shares. View RVLP analyst ratings or view top-rated stocks. What is RVL Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 1-year price objectives for RVL Pharmaceuticals' shares. Their RVLP share price targets range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 68,393.2% from the stock's current price. View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts. How have RVLP shares performed in 2023? RVL Pharmaceuticals' stock was trading at $1.12 at the beginning of 2023. Since then, RVLP shares have decreased by 99.7% and is now trading at $0.0037. View the best growth stocks for 2023 here. When is RVL Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023. View our RVLP earnings forecast. How were RVL Pharmaceuticals' earnings last quarter? RVL Pharmaceuticals plc (NASDAQ:RVLP) posted its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The business had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 130.22% and a negative net margin of 184.91%. During the same period last year, the company earned ($0.26) earnings per share. Who are RVL Pharmaceuticals' major shareholders? RVL Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Foundation Harsaul and Ltd Altchem. View institutional ownership trends. How do I buy shares of RVL Pharmaceuticals? Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RVLP) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RVL Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.